Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 136

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 136
---
38,800)$30.31 Nonvested, September 30, 2025 (unaudited)393,871$30.77 — $— 393,871$30.77 

11.    Earnings (Loss) per Share

The following table sets forth the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2025 and 2024 (dollars in thousands, except share and per share amounts):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024(unaudited)(unaudited)Numerator:Net earnings (loss)$(45,117)$38,497 $(34,445)$58,537 Denominator:Weighted average shares outstanding, basic56,552,741 55,149,760 56,133,918 54,977,199 Effect of dilutive securities:Stock options and stock awards— 866,590 — 813,986 Weighted average shares outstanding, diluted56,552,741 56,016,350 56,133,918 55,791,185 Earnings (loss) per share, basic$(0.80)$0.70 $(0.61)$1.06 Earnings (loss) per share, diluted$(0.80)$0.69 $(0.61)$1.05 The following table sets forth the common stock equivalents of outstanding stock-based awards excluded in the calculation of diluted earnings (loss) per share, because their inclusion would be anti-dilutive:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024(unaudited)(unaudited)Stock options and stock awards647,044 712,457 743,145 772,255 

28

12.    Income Tax Expense (Benefit)

The following table provides information regarding the Company's income tax expense (benefit) for the three and nine months ended September 30, 2025 and 2024 (dollars in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024(unaudited)(unaudited)Income tax expense (benefit)$(12,837)$6,446 $(12,671)$12,951 Effective tax rate22.2 %14.3 %26.9 %18.